[HTML][HTML] Preclinical and clinical status of PSMA-targeted alpha therapy for metastatic castration-resistant prostate cancer

A Juzeniene, VY Stenberg, ØS Bruland, RH Larsen - Cancers, 2021 - mdpi.com
Simple Summary Currently, there is no treatment that can cure patients with late stage metastatic
prostate cancer. Prostate-specific membrane antigen is a type of protein overexpressed …

Preparation of the alpha‐emitting prostate‐specific membrane antigen targeted radioligand [212Pb]Pb‐NG001 for prostate cancer

VY Stenberg, A Juzeniene, Q Chen… - Journal of Labelled …, 2020 - Wiley Online Library
Prostate‐specific membrane antigen (PSMA) is the most promising target for radioligand
therapy of prostate cancer. The aim of this study was to prepare a small molecular ligand p‐SCN…

An experimental generator for production of high-purity 212Pb for use in radiopharmaceuticals

RG Li, VY Stenberg, RH Larsen - Journal of Nuclear Medicine, 2023 - Soc Nuclear Med
… Ruth Li and Vilde Stenberg were industrial PhD students financially … which Vilde Stenberg
was also a shareholder at ArtBio AS. Ruth Li is employed at Oncoinvent AS, Vilde Stenberg is …

[HTML][HTML] Evaluation of the PSMA-Binding Ligand 212Pb-NG001 in Multicellular Tumour Spheroid and Mouse Models of Prostate Cancer

VY Stenberg, RH Larsen, LW Ma, Q Peng… - International journal of …, 2021 - mdpi.com
Radioligand therapy targeting the prostate-specific membrane antigen (PSMA) is rapidly
evolving as a promising treatment for metastatic castration-resistant prostate cancer. The PSMA-…

[HTML][HTML] Factors Influencing the Therapeutic Efficacy of the PSMA Targeting Radioligand 212Pb-NG001

VY Stenberg, AJK Tornes, HR Nilsen, ME Revheim… - Cancers, 2022 - mdpi.com
Simple Summary Prostate-specific membrane antigen (PSMA) is a protein overexpressed in
metastatic castration-resistant prostate cancer and a promising target for targeted …

In situ generated 212Pb-PSMA ligand in a 224Ra-solution for dual targeting of prostate cancer sclerotic stroma and PSMA-positive cells

VY Stenberg, A Juzeniene, ØS Bruland… - Current …, 2020 - ingentaconnect.com
Background: New treatments combating bone and extraskeletal metastases are needed for
patients with metastatic castration-resistant prostate cancer. The majority of metastases …

[HTML][HTML] Targeted alpha therapy with the 224Ra/212Pb-TCMC-TP-3 dual alpha solution in a multicellular tumor spheroid model of osteosarcoma

AJK Tornes, VY Stenberg, RH Larsen… - Frontiers in …, 2022 - frontiersin.org
Osteosarcoma patients with overt metastases at primary diagnosis have a 5-year survival
rate of less than 20%. TP-3 is a murine IgG2b monoclonal antibody with high affinity for an …

[HTML][HTML] The therapeutic effectiveness of 177Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest

…, M Jarlier, N Bonnefoy, S Patzke, V Stenberg… - Leukemia, 2020 - nature.com
Some patients with B-cell non-Hodkin lymphoma Lymphoma (NHL) become refractory to
rituximab (anti-CD20 antibody) therapy associated with chemotherapy. Here, the effect of the …

[HTML][HTML] Calibration of sodium iodide detectors and reentrant ionization chambers for 212Pb activity in different geometries by HPGe activity determined samples

E Napoli, VY Stenberg, A Juzeniene, GE Hjellum… - Applied Radiation and …, 2020 - Elsevier
Lead-212 is a promising radionuclide for cancer therapy, but no primary 212 Pb activity
standardization has been published. A need therefore exists for accurate estimation of injected …

Targeted alpha therapy with the

AJK Tornes, VY Stenberg, RH Larsen… - … particle therapy in …, 2023 - books.google.com
Osteosarcoma (OS) is the second most common bone cancer after chondrosarcoma, and the
most common bone malignancy in adolescents and young adults (1, 2). The 5-year survival …